Learn why combining AI-enabled trial matching with transportation, lodging, and financial assistance is essential to turning ...
In today’s ACT Brief, we examine why fragmented data systems continue to slow life sciences research, review how sponsor ...
If we can use AI or AI agents to automate those workflows, you can still run the same process, particularly as it relates to ...
In today’s ACT Brief, we cover the FDA approval of oral Wegovy based on Phase III OASIS 4 results, recap the most-read ...
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...
Review the performance, engagement, and satisfaction metrics sponsors and CROs should track to determine whether operational ...
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...
In today’s ACT Brief, we examine how sponsors are reassessing new engagement technologies to avoid increasing site burden, ...
Examine how evolving sourcing strategies, functional standardization, and system choices can help sponsors support sites more ...
In today’s ACT Brief, we examine new survey data revealing what patients value most in remote clinical trials, break down ...
In today’s ACT Brief, we look at emerging operational changes aimed at reducing site burden, review the FDA approval of GSK’s ...
Wegovy pill, the first oral GLP-1 for weight loss, is FDA-approved for reducing cardiovascular risks in adults. Phase III OASIS 4 trial showed 16.6% mean weight loss with oral semaglutide, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback